Search AXIM
AXIM BIOTECHNOLOGIES, INC.
OTC · CIK 1514946
Last close0
Daily change-0.00 (-17.50%)
10 Years gain-98.61%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
AXIM · STANDARD
SIC 2834 · Pharmaceutical Preparations · Fiscal year end 1231
Fundamental
21.8Momentum
n/aAcceleration
n/aConfidence
68.0Annual Revenue15
Quarterly Revenue43
Annual CFO12
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth7.7 / 25
Quality14.1 / 25
Capital Efficiency0.0 / 20
Balance Sheet0.0 / 15
Shareholder Economics0.0 / 10
Forward Indicators0.0 / 5
Signals
No positive signals calculated.
Warnings
Low interest coverage · HIGHInterest coverage is -1.9493x.
Key Metrics
Revenue Growth TTM932.81%OK
Revenue CAGR 3Y-13.22%OK
Gross Margin98.06%OK
Operating Margin-2,508.97%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROICn/aMISSING
Incremental Operating Margin 3Yn/aNOT_MEANINGFUL
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Yn/aINSUFFICIENT_HISTORY
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2023 FY Dec 31, 2023 | $39,518.00 | $39,518.00 | -$2.75M | -$1.03M | -$1.03M | 100% | -6,960.98% | -2,607.67% | n/a | n/a |
| 2024 FY Mar 31, 2023 | $7,397.00 | $7,397.00 | -$710,634.00 | n/a | n/a | 100% | -9,607.06% | n/a | n/a | n/a |
| 2023 FY Dec 31, 2022 | $8,875.00 | $8,875.00 | -$4.65M | -$2.04M | -$2.05M | 100% | -52,425.6% | -23,132.8% | n/a | n/a |
| 2022 FY Dec 31, 2021 | $60,460.00 | $60,460.00 | -$13.97M | -$2.49M | -$2.53M | 100% | -23,114.45% | -4,180.05% | n/a | n/a |
| 2021 FY Dec 31, 2020 | $0.00 | $0.00 | -$4.95M | -$3.22M | -$3.31M | n/a | n/a | n/a | n/a | n/a |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $89,968.00 | sum latest 4 fiscal quarters Revenue | OK | 0001096906-24-001772, 0001096906-23-002238 |
| Revenue Growth TTM | 932.81% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001096906-24-001772, 0001096906-23-002238 |
| Revenue CAGR 3Y | -13.22% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001096906-24-000864 |
| Revenue CAGR 5Y | -45.2% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001096906-24-000864 |
| Gross Profit CAGR 3Y | -13.22% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001096906-24-000864 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001096906-24-001772, 0001096906-23-002238 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 98.06% | Gross Profit / Revenue | OK | 0001096906-24-001772, 0001096906-23-002238 |
| Operating Margin | -2,508.97% | Operating Income / Revenue | OK | 0001096906-24-001772, 0001096906-23-002238 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001096906-24-001772 |
| Interest Coverage | -1.95x | Operating Income / abs(Interest Expense) | OK | derived |
| Current Ratio | 0x | Current Assets / Current Liabilities | OK | derived |
| Cash / Debt | 0x | (Cash + Short-term Investments) / Total Debt | OK | 0001096906-24-001772 |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |